Redcare Pharmacy stock faces valuation upside and execution risks
Published on 11/11/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSValuation Meets Execution Risk
- Simply Wall St estimates fair value at 88.8 euros, but its sales-based benchmark remains a key valuation risk.
- Redcare Pharmacy confirmed 2026 revenue growth guidance of 16% to 18% after higher nine-month sales and a smaller net loss.
- Logistics expansion could improve efficiency, while prescription rules and competition remain important execution tests.
Redcare Pharmacy enters the next stage of its growth story with a constructive valuation signal but clear execution risks. In an analysis published on Wednesday, November 11, Simply Wall St estimated fair value at 88.8 euros against a last close of 73.65 euros.
The analysis followed Redcare's confirmation of 2026 revenue growth guidance of 16% to 18% and its nine-month results. Simply Wall St noted higher sales and a smaller net loss, while emphasizing that the investment case still depends on the company converting scale into sustainable profitability. Its Simply Wall St analysis applies a 5.48% discount rate and long-term earnings and revenue forecasts.
Logistics Could Lift Margins
Simply Wall St identified Redcare's new Pilsen center and the Sevenum automation project as potential efficiency drivers. The projects target up to 70% lower labor cost per order and additional capacity from 2027. If implementation proceeds as planned, the investments could support adjusted EBITDA margins and net income.
The valuation picture is less uniform when measured against sales. Redcare trades at a price-to-sales ratio of 0.5 times, below peers at 0.6 times but above the analysis's estimated fair ratio of 0.1 times. That gap leaves the shares dependent on investors accepting a premium to the sales-based benchmark.
Prescription Demand Remains Crucial
The principal risks are tied to operating delivery rather than the headline revenue target. Less favorable prescription rules in Germany or elsewhere in Europe could weaken demand, while stronger non-prescription competition could increase marketing spending and pressure margins. Delays in logistics projects would also reduce the expected efficiency gains.
Redcare Pharmacy stock traded at 71.55 euros on Lang & Schwarz at 18:01 CET on Wednesday, November 11, 2026, 0.63 percent above the Xetra close of Wednesday, November 11, at 71.10 euros.
Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Xetra ticker: RDC
- Lang & Schwarz price: 71.55 euros at 18:01 CET on November 11, 2026
- Xetra close: 71.10 euros on November 11, 2026
- Market capitalization: 1.43 billion euros
- 52-week range: 30.20 to 79.90 euros
- Sector: Food and Staples Retail
European retail shares remain sensitive to interest rates, consumer demand and sector-specific competition. See the latest Euro Stoxx 50 market coverage for the broader regional setting.
